Anti-Tumour Activity of Bisphosphonates in Human Myeloma Cells

References

• Lahtinen R., Laakso M., Palva I., Virkkunen P., Elo-Maa I. Randomised, placebo controlled multicentre trial of clodronate in multiple myeloma. Lancet 1992; 340: 1049–1052
   PubMed Web of Science ®Google Scholar
• Bataille R., Chappard D., Basle M. Excessive bone resorption in human plasmacytomas: Direct induction by tumour cells in vivo. British Journal of Haematology 1995; 90: 721–724
   PubMed Web of Science ®Google Scholar
• Taube T., Beneton M. N.C., McCloskey E. V., Rogers S., Greaves M., Kanis J. A. Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. European Journal of Haematology 1992; 49: 192–198
   PubMed Web of Science ®Google Scholar
• Valentin-Opran A., Charhon S., Meunier P. J., Edouard C M., Ariot M. E. Quantitative histology of myeloma-induced bone changes. British Journal of Haematology 1982; 52: 601–610
   PubMed Web of Science ®Google Scholar
• Rossi J. F., Chappard D., Marcelli C., Laplante J., Comities T., Baldet P., Janbon C., Jourdan J., Alexandre C., Bataille R. Micro-osteoclast resorption as a characteristic feature of B-cell malignancies other than multiple myeloma. British Journal of Haematology 1990; 76: 469–475
   PubMed Web of Science ®Google Scholar
• Chappard D., Rossi J., Bataille R., Alexandre C. Osteoclast cytomorphometry demonstrates an abnormal population in B cell malignancies but not in multiple myeloma. Calcified Tissue International 1991; 48: 13–17
   PubMed Web of Science ®Google Scholar
• Bataille R., Chappard D., Marcelli C., Dessauw P., Baldet P., Sany J., Alexandre C. Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. Journal of Clinical Investigation 1991; 88: 62–66
   PubMed Web of Science ®Google Scholar
• Mundy G. R., Raisz L. G., Cooper R. A., Schechter G. P., Salmon S. Evidence for the secretion of an osteoclast stimulating factor in myeloma. New England Journal of Medicine 1974; 291: 1041–1046
   PubMed Web of Science ®Google Scholar
• Mundy G. R., Luben R. A., Raisz L. G., Oppenheim J. J., Buell D. N. Bone-resorbing activity in supernatants from lymphoid cell lines. New England Journal of Medicine 1974; 290: 867–871
   PubMed Web of Science ®Google Scholar
• Cozzolini F., Torcia M., Aldinucci D., Rubartelli A., Milani A., Shaw A., Landsorp P., Di Guglielmo R. Production of interleukin-1 by bone marrow myeloma cells. Blood 1989; 74: 380–387
   PubMed Web of Science ®Google Scholar
• Garrett I. R., Durie B. G.M., Newin G. E., Gillespie A., Bringman T, Sabatini M., Bertolini D. R., Mundy G. R. Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells. New England Journal of Medicine 1987; 317: 526–532
   PubMed Web of Science ®Google Scholar
• Kawano M., Hirano T., Matsuda T., Taga T., Horii Y., Iwato K., Asaoku H., Tang B., Tanabe O., Tanaka H., Kuramoto A., Kishimoto T. Autocrine generation and requirement of BSF-2ML-6 for human multiple myelomas. Nature 1988; 32: 83–85
   Web of Science ®Google Scholar
• Sati H. I.A., Greaves M., Apperley J. F., Russell R. G.G., Croucher P. I. Expression of IL-ip and TNFa mRNA by neoplastic plasma cells, detected by dual colour fluorescence in situ, hybridisation. Bone 1997; 20: 174, abstr.
   Google Scholar
• Dallas S. L., Garret I. R., Bonewald L. F., Gilles J., Boyce B. F., Radl J., Mundy G. R. Evidence for a vicious cycle between myeloma growth in bone and osteoclastic bone resorption. Blood 1994; 84: 176a, abstr
   PubMed Web of Science ®Google Scholar
• Barille S., Collette M., Bataille R., Amiot M. Myeloma cells upregulate interleukin-6 secretion in osteoblastic cells through cell-to-cell contact but down regulate osteocalcin. Blood 1995; 86: 685–691
   PubMedGoogle Scholar
• Garrett I. R., Dallas S. L., Bonewald L. F., Boyce B. F., Dallas M., Radl J., Mundy G. R. Evidence for bidirectional interactions between osteoclasts and myeloma cells. Journal of Bone and Mineral Research, 10: S195, (abstr.)
   Google Scholar
• Fleisch H. Bisphosphonates: pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs 1991; 42: 919–944
   PubMed Web of Science ®Google Scholar
• Hughes D. E., Wright K. R., Uy H. L., Sasaki A., Yoneda T., Roodman G. D., Mundy G. R., Boyce B. F. Bisphosphonates promote apoptosis in murine osteoclasts in vitro, and in vivo. Journal of Bone and Mineral Research 1995; 10: 1478–1487
   PubMed Web of Science ®Google Scholar
• Mönkönnen J. Frith C., Russell J. R.G.G., Blackburn G. M., Rogers M J. Clodronate and liposome-encapsu-lated clodronate can be metabolised to a toxic ATP analogue, adenosine 5′-(6,β,γ-dichloromethylene)triphosphate by mammalian cells in vitro. Journal of Bone and Mineral Research 1997; 12: 1358–1367
   PubMed Web of Science ®Google Scholar
• Luckman S. P., Hughes D. E., Coxon F. P., Russell R. G.G., Rogers M. J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-trans-lational prenylation of GTP-binding proteins, including Ras. Journal of Bone and Mineral Research 1998; 13: 581–589
   PubMed Web of Science ®Google Scholar
• Rodan G. A., Fleisch H. A. Bisphosphonates: Mechanisms of action. Journal of Clinical Investigation 1996; 97: 2692–2696
   PubMed Web of Science ®Google Scholar
• Rogers M. J., Russell R. G.G. Mechanisms of action of bisphosphonates as inhibitors of bone resorption. The molecular biology of Paget's disease, P. T. Sharpe. R.G. Landes Co, Austin, Texas 1996; 147
   Google Scholar
• Hughes D. E., Macdonald B. R., Russell R. G.G., Gowen M. Inhibition of osteoclast-like cell function by bisphosphonates in long-term cultures of human bone marrow. Journal of Clinical Investigation 1989; 83: 1930–1935
   PubMed Web of Science ®Google Scholar
• Boonekamp P., Van Der Wee-Pals L. M., Van Wijk-Van Len-Nep M. M.L., Thesing C. W., Bijvoet O. L. Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone and Mineral 1986; 1: 27–39
   PubMedGoogle Scholar
• Sahni M., Guenther H. L., Fleisch H., Collin P., Martin T. J. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. Journal of Clinical Investigation 1993; 91: 2004–2011
   PubMed Web of Science ®Google Scholar
• Nishikawa M, Akatsu T., Katayama Y., Yasutomo Y., Kada S., Kugai N., Yamamoto M., Nagata N. Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. Bone 1996; 18: 9–14
   PubMed Web of Science ®Google Scholar
• Monkkonen J., Taskinen M., Auriola S. O.K., Urtti A. Growth inhibition of macrophage-like and other cell types by liposome-encapsulated, calcium-bound, and free bisphosphonates in vitro. Journal of Drug Targeting 1994; 2: 299–308
   PubMed Web of Science ®Google Scholar
• Cecchini M. G., Felix R., Fleisch H., Cooper P. H. Effects of bisphosphonates on proliferation and viability of mouse bone marrow-derived macrophages. Journal of Bone and Mineral Research 1987; 2: 135–142
   PubMed Web of Science ®Google Scholar
• Rogers M. J., Watts D. J., Russell R. G.G., Ji X., Xiong X., Blackburn G. M., Bayless A. V., Ebetino F. H. Inhibitory effects of bisphosphonates on growth of amoebae of the cellular slime mould Dictyostelium discoideum. Journal of Bone and Mineral Research 1994; 9: 1029–1039
   PubMed Web of Science ®Google Scholar
• Fast D. K., Felix R., Dowse C., Neuman W. F., Fleisch H. The effects of diphosphonates on the growth and glycolysis of connective-tissue cells in culture. Biochemical Journal 1978; 172: 97–107
   PubMed Web of Science ®Google Scholar
• Reitsma P. H., Teitelbaum S. L., Bijvoet O. L. Differential action of the bisphosphonates (3-amino-1-hydrox-ypropylidene)- 1, 1-bisphosphonate (APD) and disodium dichloromethylidene bisphosphonate (C12MDP) on rat mac-rophage-mediated bone resorption in vitro. Journal of Clinical Investigation 1982; 70: 927–932
   PubMed Web of Science ®Google Scholar
• Van Der Pluijm G., Vloedgraven H., Van Beek E., Wee-Van Der Pals L., Lowik C., Papapoulos S. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. Journal of Clinical Investigation 1996; 98: 698–705
   PubMed Web of Science ®Google Scholar
• Rogers M. J., Chilton K. M., Coxon F. P., Lawry J., Smith M. O., Suri S., Russell R. G.G. Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro, by a nitric oxide-independent mechanism. Journal of Bone and Mineral Research 1996; 11: 1482–1491
   PubMed Web of Science ®Google Scholar
• Delmas P. D., Meunier P. J. The management of Paget's disease of bone. New England Journal of Medicine 1997; 336: 558–566
   PubMed Web of Science ®Google Scholar
• Belch A. R., Bergsagel D. E., Wilson K., O'Reilly S., Wilson J., Sutton D., Pater J., Johnston D., Zee B. Effect of daily etidronate on the osteolysis of multiple myeloma. Journal of Clinical Oncology 1991; 9: 1397–1402
   PubMed Web of Science ®Google Scholar
• Daragon A., Humez C., Michot C., Leloet X., Grosbois B., Pouyol F., Euller-Ziegler L., Azais I., Bernard J. F., Monconduit M. Treatment of multiple myeloma with etidronate: Results of a multicentre double-blind study. European Journal of Medicine 1993; 2: 449–452
   PubMedGoogle Scholar
• McCloskey E. V., Maclennan I. C.M., Drayson M. T., Chapman C., Dunn J., Kanis J. A. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. British Journal of Haematology 1998; 100: 317–325
   PubMed Web of Science ®Google Scholar
• Berenson J., Lichtenstein A., Porter L., Dimopoulos M., Bordoni R., George S., Lipton A., Keller A., Ballester O, Kovacs M., Blacklock H., Bell R., Simeone J., Reitsma D., Heffernan M., Seaman J., Knight R. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. New England Journal of Medicine 1996; 334: 488–493
   PubMed Web of Science ®Google Scholar
• Brincker H., Westin J., Abilgaard N., Gimsing P., Turesson I., Hedenus M., Ford J., Kandra A. Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. British Journal of Haematology 1998; 101: 280–286
   PubMed Web of Science ®Google Scholar
• Roux C., Ravaud P., Cohen-Solal M., De Vernejoul M. C., Guillemant S., Cherruau B., Delmas P., Dougados M., Amor B. Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma. Bone 1994; 15: 41–49
   PubMed Web of Science ®Google Scholar
• Riccardi A., Ucci G., Brugnatelli S., Mora O., Merlini G., Piva N., De Paoli A., Barbarano L., Di Stasi M., Alberio E, Nicoletti G., Moransi S., Rinaldi E., Piccini L., Ascari E. A prospective, controlled, non-randomized study on prophylactic parenteral dichloromethylene bisphosphonate (clodronate) in multiple myeloma. International Journal of Oncology 1994; 5: 833–839
   PubMed Web of Science ®Google Scholar
• McCloskey E. V., Maclennan I. C.M., Drayson M., Chapman C., Dunn J., Kanis J. A. Effect of clodronate on morbidity and mortality in myelomatosis. Annals of Oncology 1996; 7: 4120, abstr
   Google Scholar
• Berenson J. R., Lichtenstein A., Porter L., Dimopoulos M. A., Bordoni R., George S., Lipton A., Keller A., Ball-Ester O., Kovacs M., Blacklock H., Bell R., Simeone J. F., Reitsma D. J., Heffernan M., Seaman J., Knight R. D. Long-term pamidronate treatment of avanced multiple myeloma patients reduces skeletal events. Journal of Clinical Oncology 1998; 16: 593–602
   PubMed Web of Science ®Google Scholar
• Geddes A. D., D'Souza S. M., Ebetino F. H., Ibbotson K. J. Bisphosphonates; structure-activity relationships and therapeutic implications. Bone and Mineral Research 1994; 8: 265–306
   Google Scholar
• Shipman C. M., Rogers M. J., Apperley J. F., Russell R. G.G., Croucher P. I. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. British Journal of Haematology 1997; 98: 665–672
   PubMed Web of Science ®Google Scholar
• Wyllie A., Kerr J. F.R., Currie A. R. Cell Death: The significance of Apoptosis. International Review of Cytology 1980; 68: 251–306
   PubMedGoogle Scholar
• Gerschenson L. E., Rotello R. J. Apoptosis: A different type of cell death. FASEB Journal 1992; 6: 2540–2455
   Google Scholar
• Kerr J. F.R., Winterford C M., Harmon B. V. Apoptosis: Its significance in cancer and cancer therapy. Cancer 1994; 73: 2013–2026
   PubMed Web of Science ®Google Scholar
• Green J. R., Miiller K., Jaeggi K. A. Preclinical pharmacology of CGP 42′466, a new, potent heterocyclic bisphosphonate compound. Journal of Bone and Mineral Research 1994; 9: 745–751
   PubMed Web of Science ®Google Scholar
• Aparichio A., Gardner A., Tu Y., Berenson J., Lichtenstein A. In vitro, cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 1998; 12: 220–229
   PubMed Web of Science ®Google Scholar
• Wingen E, Pool B. L., Klein P., Klenner T., Schmahl D. Anticancer activity of bisphosphonic acids in methylnitrosourea-induced mammary carcinoma of the rat; benefit of combining bisphosphonates with cytostatic agents. Investigational New Drugs 1988; 6: 155–167
   PubMed Web of Science ®Google Scholar
• Wingen F., Klenner T., Schmahl D. Are all anticancer effects of pamidronate (APD) and related compounds bone-mediated?. The Management of Bone Metastases and Hypercalcaemia by Osteoclast Inhibition. Fifth European Conference on Clinical Oncology. Hogrefe and Huber, Bern 1989; 111
   Google Scholar
• Radl J., Croese J. W., Zurcher C., Van Den Endenvieveen M. H.M., Brondijk R. J., Kazil M., Haajman J. J., Reitsma P. H., Bijvoet O. L.M. Influence of treatment with APD-bisphosphonate in the mouse 5T2 multiple myeloma. Cancer 1985; 55: 1030–1040
   PubMed Web of Science ®Google Scholar
• Sasaki A., Boyce B. F., Story B., Wright K. R., Chapman M., Boyce R., Mundy G. R., Yoneda T. Bisphos-phonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Research 1995; 55: 3551–3557
   PubMed Web of Science ®Google Scholar
• Berenson J. R. Bisphosphonates in multiple myeloma. Cancer 1997; 80: 1661–1667
   PubMed Web of Science ®Google Scholar